Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy

Epilepsia

Volumn 47, Issue 2, 2006, Pages 233-239

  Wang Tilz, Ying ^a   Tilz, Christian ^a   Wang, Bing ^b,c   Tilz, Gernot P ^d   Stefan, Hermann ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Coriaria lactone animal model; Lamotrigine; Multidrug resistance gene 1 (MDR1); Pharmacoresistant temporal lobe epilepsy; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GLYCOPROTEIN P; LAMOTRIGINE; MULTIDRUG RESISTANCE PROTEIN 1; SODIUM CHLORIDE; TOPIRAMATE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; GENE OVEREXPRESSION; IMAGE ANALYSIS; MALE; MEASUREMENT; MONITORING; MONOTHERAPY; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; TEMPORAL LOBE EPILEPSY;

ANIMALS; ANTICONVULSANTS; BRAIN; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; EPILEPSY, TEMPORAL LOBE; FRUCTOSE; GENE EXPRESSION; GENES, MDR; HUMANS; IMMUNOHISTOCHEMISTRY; KINDLING, NEUROLOGIC; LACTONES; MALE; P-GLYCOPROTEIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TRIAZINES; VALPROIC ACID;

EID: 33645278340     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00414.x     Document Type: Article

References (52)

1. Forsgren L. Prospective incidence study and clinical characterization of seizures in newly referred adults. Epilepsia 1990 31 292 301.
2. Cockerell OC Johnson AL Sander JWAS et al. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995 346 140 144.
3. Morrow CS Cowan KH. Mechanisms and clinical significance of multidrug resistance. Oncology 1988 2 55 63.
4. Tishler DV Weinberg KI Hinton DR et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995 36 1 6.
5. Lazarowski A Sevlever G et al. Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999 21 731 734.
6. Sisodiya SM Heffernan J Squier MV. Over-expression of P glycoprotein in malformations of cortical development. Neuroreport 1999 10 3437 3441.
7. Sosidiya SM Lin WR Harding BN et al. Drug resistance in epilepsy: expression of drug resistance protein in common cause of refractory epilepsy. Brain 2002 125 22 31.
8. Löscher W Heidrum P. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002 301 7 14.
9. Volk HA Potschka H Löcher W. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004 58 67 69.
10. Lararowski A Ramos AJ Garcia-Rivello H et al. Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model. Cell Mol Neurobiol 2004 24 77 85.
11. Sisodiya SM Martinian L Scheffer GL et al. Vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 2003 44 1388 1396.
12. Marroni M Marchi N Cucullo L et al. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. Curr Drug Targets 2003 4 297 304.
13. Schinkel AH. The physiological function of drug-transporting P-glycoprotein. Semin Cancer Biol 1997 8 161 170.
14. Cordon-Cardo C O'Brien JP Casals D et al. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989 86 695 698.
15. Potschka H Fedrowitz M Löscher W. Multidrug resistance protein MRP2 contributes to blood brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003 306 124 131.
16. Seegers U Potschka H Löscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. Eur J Pharmacol 2002 451 149 155.
17. Potschka H Fedrowitz M Löscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002 327 173 176.
18. Wang Y Zhou D Wang B et al. A kindling model of pharmacoresistant temporal lobe epilepsy in Sprague-Dawley rats induced by Coriaria lactone and its possible mechanisms. Epilepsia 2003 44 475 488.
19. Seegers U Potschka H Löscher W. Expression of the multidrug transporter P-glycoprotein in brain capillary endothelial cells and brain parenchyma of amygdala-kindled rats. Epilepsia 2002 43 675 684.
20. Racine RJ. Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 1974 32 281 294.
21. Xie YG Chai HX Zeng H et al. An experimental model of epilepsy induced by the administration of Coriaria lactone in rabbits. Acta Acad Med Sichuan 1981 12 289 294.
22. Chai HX Xie YG Chen QX et al. A rat model of epilepsy induced by Coriaria lactone. Acta Acad Med Sichuan 1983 14 283 287.
23. Chai HX Xie YG Liu XL et al. An epileptic kindling model induced by Coriaria lactone in rats. Chin J Psychiatry Neurol 1991 24 367 369.
24. Liao DY Wu LF Li XQ et al. An epileptic model of the acute motor pattern induced by Coriaria lactone in rats. J West China Univ Med Sci (J WCUMS) 1987 18 97 100.
25. Liao DY Wu LF Li XQ et al. An epileptic model of the partial somatomotor status epilepticus induced by Coriaria lactone in rats. J WCUMS 1987 18 101 103.
26. Wu LF Liao DY Li XQ et al. An epileptic model of the generalized convulsion type of kindling induced by Coriaria lactone in rats. J WCUMS 1987 18 104 106.
27. Stefan H Wang Y Kerling F et al. Therapeutic intensive seizure analysis (TISA) in presurgical evaluation of losigamone. Acta Neurol Scand 2001 104 195 201.
28. Stefan H Wang Y Zhou D et al. Therapeutic intensive seizure analysis (TISA) used in presurgical evaluation of intravenous monohydroxy derivative of oxcarbazepine (MHD). Epilepsia 2000 41 suppl 7 116.
29. Wang Y Zhou D Pauli E et al. Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study. Epilepsy Res 2001 46 269 275.
30. Zhou D Wang Y Hopp P et al. Influence of acute AEDs withdrawal on seizure semiology: a prospective and quantitative TISA study. Epilepsia 2000 41 suppl 7 115.
31. Löscher W Cramer S Ebert U. Selection of phenytoin responders and nonresponders in male and female amygdala-kindled Sprague-Dawley rats. Epilepsia 1998 39 1138 1147.
32. Rundfeldt C Löscher W. Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala-kindled rats. J Pharmacol Exp Ther 1993 266 216 223.
33. Wang L Zhang JT Xu SG et al. Effects of eight antiepileptic drugs on Coriaria and electric induced convulsion and impairment of learning and memory in mice. Acta Pharmaceut Sin 1988 23 490 493.
34. Bao DY. Conversion ratio of equivalent drug dosage calculation in animal experiments according to body surface area. In Bao DY ed. Pharmacological Experiments Guideline. Sichuan: Chengdu Technological University Publishing House 1984 102.
35. Chen MK Strande LF Beierle EA et al. Fas-mediated induction of hepatocyte apoptosis in a neuroblastoma and hepatocyte coculture model. J Surg Res 1999 84 82 87.
36. Sharma RP. Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophr Res 2005 72 79 90.
37. Baker EK El-Osta A. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 2003 290 177 194.
38. Marroni M Marchi N Cucullo L et al. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. Curr Drug Targets 2003 4 297 304.
39. Potschka H Löscher W. A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats. Neuroreport 2002 13 167 171.
40. Potschka H Löscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001 42 1231 1240.
41. Potschka H Baltes S Löscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood brain barrier penetration of levetiracetam in rats. Epilepsy Res 2004 58 85 91.
42. Chin KV Tanaka S Darlington G et al. Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 1990 265 221 226.
43. Mickley LA Bates SE Richtert ND et al. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J Biol Chem 1989 264 18031 18040.
44. Richert ND Aldwin L Nitecki D et al. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 1988 27 7607 7613.
45. Alemán C Annereau JP Liang XL et al. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alteration in membrane fluidity or membrane potential. Cancer Res 2003 63 3084 3091.
46. Muller M. Transcriptional control of hepatocanalicular transporter gene expression. Semin Liver Dis 2000 20 323 337.
47. Staudinger JL Madan A Carol KM et al. Regulation of drug transporter gene expression by nuclear receptors. Drug Metab Dispos 2003 31 523 527.
48. Bauer B Hartz AM Fricker G Miller DS. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004 66 413 419.
49. Baillie TA Sheffels PR. Valproic acid: chemistry and biotransformation. In Levy RH Mattson RH Meldrum BS eds. Antiepileptic Drugs 4th ed. New York Raven Press 1995 589 603.
50. Sakashita K Koike K Kinoshita T et al. Dynamic DNA methylation change in the CpG island region of p15 during human myeloid development. J Clin Invest 2001 108 1195 1204.
51. Marroni M Agrawal ML Kight K et al. Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene protein in human brain astrocytes. Neuroscience 2003 121 605 617.
52. Gould S Sidaway J Sansom N et al. Phenobarbitone-induced liver response in wild type and in p53 deficient mice. Toxicol Lett 2001 122 131 140.